Shares of Avinger Inc (NASDAQ:AVGR) have earned a consensus recommendation of “Hold” from the six brokerages that are covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and two have issued a buy rating on the company.
A number of analysts have commented on AVGR shares. Zacks Investment Research upgraded Avinger from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Wednesday, January 3rd. Ladenburg Thalmann Financial Services started coverage on Avinger in a research report on Friday, March 9th. They issued a “buy” rating on the stock.
In related news, insider Himanshu Patel acquired 50 shares of Avinger stock in a transaction dated Friday, February 16th. The shares were acquired at an average cost of $1,000.00 per share, for a total transaction of $50,000.00. Following the completion of the transaction, the insider now directly owns 2,484 shares of the company’s stock, valued at $2,484,000. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.80% of the stock is owned by corporate insiders.
Avinger (NASDAQ AVGR) traded down $0.11 on Friday, reaching $1.17. The company’s stock had a trading volume of 1,160,000 shares, compared to its average volume of 684,129. The stock has a market capitalization of $0.96, a P/E ratio of -0.01 and a beta of 0.88. Avinger has a one year low of $0.95 and a one year high of $85.00.
Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system.
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.